SymBiosis Capital Partners, LLC

CIK 0002006045 · BENTONVILLE, AR · Quarter end: 2026-03-31 · Filed on: 2026-05-12 · Open the SEC source ↗

SymBiosis Capital Partners, LLC reported 6 positions worth $52.8M as of March 31, 2026 (13F filed May 12, 2026). Largest holding: EVMN (55.8%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$52.8M

2026 Q1

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q1

Positions Changes Mix History BacktestPRO

6 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	EVMN	Evommune, Inc.	SH	$29.4M	55.80%	1,280,778	—	—
▸ 2	IVA	Inventiva S.A.	SH	$13.1M	24.76%	2,354,000	—	—
▸ 3	Y95308105	Wave Life Sciences Ltd.	SH	$5.4M	10.30%	750,000	—	—
▸ 4	RANI	Rani Therapeutics Holdings, Inc.	SH	$2.7M	5.11%	3,667,585	—	—
▸ 5	CLNN	Clene Nanomedicine Inc.	SH	$2.1M	4.03%	431,094	—	—
▸ 6	86889P117	Surrozen, Inc.	SH	$2.4K	0.01%	150,000	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does SymBiosis Capital Partners, LLC hold as of Q1 2026?

SymBiosis Capital Partners, LLC reported 6 positions worth $52.8M in its Q1 2026 13F filing. Largest positions: EVMN (55.8%), IVA (24.8%), Wave Life Sciences Ltd. (10.3%), RANI (5.1%) and CLNN (4.0%).

What did SymBiosis Capital Partners, LLC buy in Q1 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did SymBiosis Capital Partners, LLC sell in Q1 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.